A patient started on olanzapine 10 mg daily is asked which side effects to monitor. Which is the most important side effect to highlight at dispensing?

A patient started on olanzapine 10 mg daily is asked which side effects to monitor. Which is the most important side effect to highlight at dispensing?

• A. Dizziness
• B. Hair loss
• C. Weight gain
• D. Signs of high blood sugar such as excessive thirst and urination

Answer: (D)

Olanzapine carries a notable risk of metabolic effects, including hyperglycemia and diabetes. The most important side effect to highlight at dispensing is signs of high blood sugar—such as excessive thirst and urination—because these symptoms can indicate new or worsening diabetes and need prompt assessment. Teaching the patient to watch for polydipsia and polyuria helps catch a potentially serious issue early, reducing the risk of complications. Dizziness can occur with many medicines but is less specific and urgent than hyperglycemia, and hair loss is not a common, clinically critical concern with this drug. Weight gain is a frequent outcome and contributes to metabolic risk, so it should be monitored, but recognizing hyperglycemia first enables quicker intervention if diabetes develops. Contextually, baseline metabolic screening (fasting glucose or HbA1c, lipids, weight, blood pressure) and periodic monitoring are advised with olanzapine. Encourage the patient to report increased thirst, frequent urination, or any rapid weight changes to their prescriber and arrange follow-up as needed.

Olanzapine carries a notable risk of metabolic effects, including hyperglycemia and diabetes. The most important side effect to highlight at dispensing is signs of high blood sugar—such as excessive thirst and urination—because these symptoms can indicate new or worsening diabetes and need prompt assessment. Teaching the patient to watch for polydipsia and polyuria helps catch a potentially serious issue early, reducing the risk of complications.

Dizziness can occur with many medicines but is less specific and urgent than hyperglycemia, and hair loss is not a common, clinically critical concern with this drug. Weight gain is a frequent outcome and contributes to metabolic risk, so it should be monitored, but recognizing hyperglycemia first enables quicker intervention if diabetes develops.

Contextually, baseline metabolic screening (fasting glucose or HbA1c, lipids, weight, blood pressure) and periodic monitoring are advised with olanzapine. Encourage the patient to report increased thirst, frequent urination, or any rapid weight changes to their prescriber and arrange follow-up as needed.